Faculty, Staff and Student Publications
Open-access journal articles from UTHealth GSBS faculty, staff and students.
Submissions from 2023
Widespread BRCA1/2-Independent Homologous Recombination Defects Are Caused by Alterations in RNA-Binding Proteins, Daniel J McGrail, Yang Li, Roger S Smith, et al.
Feature Selection for Support Vector Regression Using a Genetic Algorithm, Shannon B McKearnan, David M Vock, G Elisabeta Marai, et al.
Model-Informed Drug Development of Autologous Car-T Cell Therapy: Strategies to Optimize Car-T Cell Exposure Leveraging Cell Kinetic/Dynamic Modeling, Anna M Mc Laughlin, Peter A Milligan, Cassian Yee, et al.
Letter to the Editor: Quality Criteria for Computational Models Predicting Individual Outcomes in CAR-T Cell Therapy, Anna M Mc Laughlin and Cassian Yee
Contribution of the Oral and Gastrointestinal Microbiomes to Bloodstream Infections in Leukemia Patients, Stephanie McMahon, Pranoti Sahasrabhojane, Jiwoong Kim, et al.
Antibody Toolkit to Investigate eEF1A Methylation Dynamics in mRNA Translation Elongation, Robert Mealey-Farr, Jinho Jeong, Juhyung Park, et al.
Mass Spectrometry Based Biomarkers for Early Detection of Hcc Using a Glycoproteomic Approach, Yehia Mechref, Wenjing Peng, Sakshi Gautam, et al.
Corrigendum to “Epstein-Barr-Virus-Positive Large B-Cell Lymphoma Associated With Breast Implants: An Analysis of Eight Patients Suggesting a Possible Pathogenetic Relationship” [Modern Pathology 34 (2021) 2154–2167], L Jeffrey Medeiros, Mario L Marques-Piubelli, Valentina F I Sangiorgio, et al.
Clinical Insights Into Small Cell Lung Cancer: Tumor Heterogeneity, Diagnosis, Therapy, and Future Directions, Zsolt Megyesfalvi, Carl M Gay, Helmut Popper, et al.
Unfolding the Secrets of Small Cell Lung Cancer Progression: Novel Approaches and Insights Through Rapid Autopsies, Zsolt Megyesfalvi, Simon Heeke, Benjamin J Drapkin, et al.
Characterizing the Interplay of Treatment Parameters and Complexity and Their Impact on Performance on an IROC IMRT Phantom Using Machine Learning, Hunter Mehrens, Andrea Molineu, Nadia Hernandez, et al.
Analysis of Performance and Failure Modes of the IROC Proton Liver Phantom, Hunter Mehrens, Paige Taylor, Paola Alvarez, et al.
HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection, Rohtesh S Mehta, Kai Cao, Rima M Saliba, et al.
ZRANB1 Is an NBS1 Deubiquitinase and a Potential Target to Overcome Radioresistance and PARP Inhibitor Resistance in Triple-Negative Breast Cancer, Ying Mei, Qinglei Hang, Hongqi Teng, et al.
ZRANB1 Is an NBS1 Deubiquitinase and a Potential Target To Overcome Radioresistance and PARP Inhibitor Resistance in Triple-Negative Breast Cancer, Ying Mei, Qinglei Hang, Hongqi Teng, et al.
Multifaceted Role for p53 in Pancreatic Cancer Suppression, Stephano S Mello, Brittany M Flowers, Pawel K Mazur, et al.
A Human Stem Cell-Derived Neuronal Model of Morphine Exposure Reflects Brain Dysregulation In Opioid Use Disorder: Transcriptomic and Epigenetic Characterization of Postmortem-Derived Ipsc Neurons, Emily F Mendez, Sandra L Grimm, Laura Stertz, et al.
A Comprehensive Assessment of Cell Type-Specific Differential Expression Methods in Bulk Data, Guanqun Meng, Wen Tang, Emina Huang, et al.
Inhibition of the Interaction Between Hippo/Yap and Akt Signaling With Ursolic Acid and 3’3-Diindolylmethane Suppresses Esophageal Cancer Tumorigenesis, Ruo Yu Meng, Cong Shan Li, Dan Hu, et al.
The Effect Direction Should Be Taken Into Account When Assessing Small-Study Effects, Zhuo Meng, Chong Wu, and Lifeng Lin
Bronchial Epithelial Gene Expression and Interstitial Lung Abnormalities, Aravind A Menon, Minyi Lee, Xu Ke, et al.
3-Phosphoinositide-Dependent Kinase 1 Drives Acquired Resistance to Osimertinib, Ismail M Meraz, Mourad Majidi, Bingliang Fang, et al.
Author Correction: 3-Phosphoinositide-Dependent Kinase 1 Drives Acquired Resistance to Osimertinib, Ismail M Meraz, Mourad Majidi, Bingliang Fang, et al.
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study, Funda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, et al.
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study, Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.